Biomarker 14-3-3eta Reflects RA Disease Activity, Treatment Response


EULAR 2013: Data to support effectiveness of a new biomarker test for rheumatoid arthritis that is already on the market have now been reported in a public presentation.

Researchers have now publicly reported data to support use of the marker 14-3-3eta as a supplemental test in assessment of rheumatoid arthritis (RA). Seropositivity for 14-3-3eta indicates more severe disease activity, while low titers of the biomarker may indicate a good response to anti-tumor necrosis-alpha (TNFα) therapy, according to a report at the EULAR conference in Madrid by Walter Maksymowych MD, a professor of rheumatology at the University of Alberta, and others.

An analysis of serum 14-3-3eta in banked blood samples from 112 patients with established and early RA from three study cohorts, these results held even in those patients with low C-reactive protein (CRP) levels.

The soluble marker 14-3-3eta is a regulatory intracellular protein that activates pro-inflammatory cytokines that drive joint damage. An assay for 14-3-3eta is being marketed in the US as a laboratory-developed test.

Levels of 14-3-3eta were measured at baseline in patients with established RA from the RAPPORT cohort (n=75) and the early RA TEACH and COBRA cohorts (n=37). The majority were women with a median age of 57 and were biologic-nave. Among the total group, 92 (82%) were 14-3-3 eta positive and 20 (18%) tested negative.

The 75 patients with established RA in the RAPPORT trial were given anti-TNFα therapy, and 14-3-3eta serum was measured at around 15 weeks post-treatment. Among these patients, the 20% who achieved a Good EULAR response had significantly lower median 14-3-3eta at baseline (0.72 ng/ml) compared to those who did not respond as well (2.52 ng/ml).
Low CRP did not correspond with treatment response. Among the 36% (n=27) of the 75 RAPPORT patients who had a baseline CRP ≤ 10mg/L, the seven (26%) who achieved a Good EULAR response had a nearly undetectable median 14-3-3 eta, while the 20 patients who did not respond had median levels of 3.5ng/ml at baseline.

Although the EULAR abstracts are no longer available online, an image of the poster, reproduced on a patient-authored blog has been publicized on social media. It has generated robust response from patients with RA curious about whether and how to obtain the test.

Recent Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.